论文部分内容阅读
目的:建立人血浆中美普他酚浓度的HPLC-MS/MS测定法。方法:血浆样品500μL经液-液萃取后,以10 mmol.L-1醋酸铵(含0.5%甲酸水溶液)-乙腈(70∶30)为流动相,采用InertsilCN(150 mm×4.6 mm,3.5μm)柱分离,采用电喷雾电离化(ESI)方式和多反应离子监测(MRM)模式进行正离子检测。用于定量分析的离子反应分别为m/z 234.2→107.0(美普他酚)和m/z 152.0→110.0(对乙酰氨基酚)。结果:美普他酚血药浓度线性范围为0.20～508.00μg.L-1,定量下限为0.20μg.L-1。低、中、高3个浓度提取回收率分别为68.1%,67.0%,65.6%。结论:该法操作简便、快速、灵敏,适用于美普他酚的药代动力学研究及制剂的生物等效性评价。
OBJECTIVE: To establish an HPLC-MS / MS method for the determination of meptazinol in human plasma. Methods: 500μL of plasma samples were extracted by liquid-liquid extraction with 10 mmol·L-1 ammonium acetate (containing 0.5% formic acid in water) -acetonitrile (70:30) as mobile phase and InertsilCN (150 mm × 4.6 mm, 3.5μm) column. Positive ion detection was performed by electrospray ionization (ESI) and multi-reaction ion monitoring (MRM). The ion reactions used for quantitative analysis were m / z 234.2-> 107.0 (meptazinol) and m / z 152.0-> 110.0 (paracetamol), respectively. Results: The linear range of meptazidol was 0.20 ~ 508.00μg.L-1, and the lower limit of quantitation was 0.20μg.L-1. The recoveries of low, medium and high concentrations of 3 were 68.1%, 67.0%, 65.6% respectively. Conclusion: The method is simple, rapid, sensitive and suitable for the study of pharmacokinetics of meptazinol and the bioequivalence evaluation of the preparation.